Clinical trials

  • [AL[18F]F]FAPI-74 for Progressive pulmonary fibrosis | Pulmonary fibrosis
  • Gemcitabine for Non-muscle invasive bladder cancer (intermediate-risk)
  • AMG 193 for Advanced MTAP-null solid tumors | Non-small cell lung cancer | Metastatic biliary cancer | Pancreatic ductal adenocarcinoma
  • DATOPOTAMAB DERUXTECAN for Triple-negative breast cancer
  • AMG 509 for Metastatic castration-resistant prostate cancer | Castration-resistant prostate cancer
  • ERENUMAB for Episodic migraine
  • TRASTUZUMAB DERUXTECAN for Non-small cell lung cancer with HER2 exon 19 or 20 mutations
  • FREXALIMAB for Multiple sclerosis | Secondary progressive multiple sclerosis (non-relapsing)
  • ELACESTRANT DIHYDROCHLORIDE for Breast cancer (hormone receptor-positive, HER2-negative) with gBRCA1/2 mutations (locally advanced or metastatic)
  • TACROLIMUS for Breast cancer-related lymphedema | Lymphedema
  • SAR441344 for Multiple sclerosis | Relapsing multiple sclerosis
  • BLINATUMOMAB for Acute lymphoblastic leukaemia (B-cell precursor, Philadelphia-negative)